FrancophonIA/ELRC3.0 huggingface dataset:
English: Increlex works in the same way as natural IGF-1, replacing the missing hormone and helping the child to grow taller.
Estonian: Increlex toimib samal viisil kui looduslik IGF-1, asendades puuduvat hormooni ja aidates lapsel kasvada pikemaks.
English: IGF-1 is important in determining how tall a child grows.
Estonian: IGF-1 määrab suuresti ära selle, kui pikaks laps kasvab.
English: It does this by stimulating cells to divide and grow and to absorb nutrients, supporting the growth of body tissues.
Estonian: Nimelt stimuleerib see hormoon rakkude jagunemist ja kasvu ning toitainete omastamist, toetades kehakudede kasvu.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Increlex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Increlexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The company that makes Increlex will carry out a long-term study looking at the safety of the medicine, when treatment is started in young children and continued into adulthood.
Estonian: Increlexi tootja viib läbi pikaajalise uuringu ravimi ohutuse kohta ravi alustamisel lapseeas ja jätkamisel täiskasvanueas.
English: This increased to 8.0 cm in the first year of treatment and 5.8 cm in the second.
Estonian: See suurenes esimesel aastal 8,0 cm-ni ja teisel aastal 5,8 cm-ni.
English: Treatment should be interrupted if the patient cannot eat for any reason.
Estonian: Kui patsient ei saa mingil põhjusel süüa, tuleb ravi katkestada.
English: One study compared Increlex with placebo (a dummy treatment) in eight patients, but the others did not compare Increlex with any other treatments.
Estonian: Ühes uuringus võrreldi Increlexi kasutamist platseeboga (näiv ravim) kaheksal patsiendil, kuid teistes uuringutes Increlexi muude ravimitega ei võrreldud.
English: Other information about Increlex
Estonian: Muu teave Increlexi kohta
English: Increlex has been studied in five studies involving a total of 76 children aged between one and 15 years with severe primary IGF-1 deficiency, nine of whom had received another type of recombinant IGF-1 before joining these studies.
Estonian: Increlexi kasutamist uuriti viies uuringus, milles osales kokku 76 raske primaarse IGF-1 puudulikkusega 1-15-aastast last, kellest üheksa olid saanud enne uuringutes osalemist teistsugust rekombinantset IGF-1.
English: Increlex caused the speed of growth to increase.
Estonian: Increlex kiirendas kasvu.
English: The company applied for an authorisation to use Increlex in these children, but withdrew its application after the end of the medicine's assessment, as this disease is not listed in the medicine's ‘orphan' designation.
Estonian: Ettevõte taotles müügiluba Increlexi kasutamiseks ka nende laste raviks, kuid võttis oma taotluse pärast ravimi hindamist tagasi, sest seda haigust ei sisaldu ravimi harvikravimiks nimetamise märkes.
English: The company will also supply dose calculators to help doctors and patients (or their carers) to work out the appropriate dose.
Estonian: Ettevõte turustab ka annusekalkulaatoreid, mis aitavad arstidel ja patsientidel (või nende hooldajatel) arvutada vajaliku annuse.
English: Some of the studies also included children who had defects in the gene for growth hormone (GH) and who had developed antibodies against GH.
Estonian: Mõnes uuringus osalesid lapsed, kellel oli kasvuhormooni geeni defekte ja kellel olid tekkinud kasvuhormooni vastased antikehad.
English: When the results of the studies were looked at together, the average growth rate was 2.8 cm per year before treatment.
Estonian: Kõigi uuringute kokkuvõttes oli keskmine kasvukiirus enne ravi 2,8 cm aastas.
English: The maximum dose is 0.12 mg per kilogram twice a day.
Estonian: Suurim annus on 0,12 mg kilogrammi kohta kaks korda ööpäevas.
English: For the full list of all side effects and restrictions with Increlex, see the package leaflet.
Estonian: Increlexi kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The dose should be tailored for each patient according to the speed of growth and side effects.
Estonian: Annust tuleb patsiendile individuaalselt kohandada olenevalt kasvu kiirusest ja kõrvalnähtudest.
English: The CHMP decided that Increlex's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Increlexi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: What information is still awaited for Increlex?
Estonian: Mis teavet Increlexi kohta veel oodatakse?
English: This is a summary of the European public assessment report (EPAR) for Increlex.
Estonian: See on ravimi Increlex Euroopa avaliku hindamisaruande kokkuvõte.
English: The most common side effects with Increlex (seen in more than 1 patient in 10) are headache, hypoglycaemia (low blood sugar levels), vomiting (being sick), injection site hypertrophy (lumps at the site of injection) and otitis media (infection of the middle ear).
Estonian: Increlexi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peavalu, hüpoglükeemia (vere väike glükoosisisaldus), oksendamine, süstekoha hüpertroofia (mügarad süstekohal) ja keskkõrvapõletik.
English: The recommended starting dose is 0.04 mg per kilogram body weight twice a day.
Estonian: Soovituslik algannus on 0,04 mg kehamassi kilogrammi kohta kaks korda ööpäevas.
English: Because the number of patients with primary IGF-1 deficiency is low, the disease is considered ‘rare', and Increlex was designated an ‘orphan medicine' (a medicine used in rare diseases) on 22 May 2006.
Estonian: Et primaarse IGF-1 puudulikkusega patsiente on vähe ja see haigus esineb harva, nimetati Increlex 22. mail 2006 harvikravimiks.
English: Increlex is a solution for injection that contains the active substance mecasermin.
Estonian: Increlex on süstelahus, mis sisaldab toimeainena mekasermiini.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Increlex, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Increlexi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: Treatment with Increlex should be stopped if neoplasia develops.
Estonian: Neoplaasia tekkimisel tuleb ravi Increlexiga katkestada.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Increlex.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: The growth rate stabilised at around 4.7 cm per year from the fourth year of treatment.
Estonian: Alates 4. raviaastast stabiliseerus kasvukiirus ligikaudu 4,7 cm-ni aastas.
English: Increlex is used for the long-term treatment of patients aged two to 18 years who are short for their age due to a condition known as ‘severe primary insulin-like growth factor-1 deficiency'.
Estonian: Increlexi kasutatakse nende 2-18-aastaste patsientide kasvuhäire pikaajaliseks raviks, kes on oma vanuse kohta lühikesed, mida põhjustab insuliinisarnase kasvuteguri I (IGF-1) raske primaarne puudulikkus.
English: Increlex must not be used in patients who have, or are thought to have active neoplasia (abnormal cell growth).
Estonian: Seda ei tohi kasutada ka patsiendid, kellel on aktiivne neoplaasia (rakkude ebanormaalne kasv) või selle kahtlus.
English: It should never be injected into a vein.
Estonian: Ravimit ei tohi süstida veeni.
English: Patients with this condition have low levels of the hormone insulin-like growth factor-1 or IGF-1, which is required for normal growth.
Estonian: Selle haigusega patsientidel on normaalseks kasvuks vajaliku hormooni, insuliinisarnase kasvuteguri I (IGF-1) vähesus.
English: What is the risk associated with Increlex?
Estonian: Mis riskid Increlexiga kaasnevad?
English: The active substance in Increlex, mecasermin, is a copy of the hormone IGF-1.
Estonian: Increlexi toimeaine mekasermiin on hormooni IGF-1 tehisteisend.
English: What benefit has Increlex shown during the studies?
Estonian: Milles seisneb uuringute põhjal Increlexi kasulikkus?
English: Additionally, the company that markets Increlex will supply information packs to doctors and patients explaining how the medicine is used and its side effects.
Estonian: Lisaks varustab Increlexi tootja arstid ja patsiendid teabepakmega, milles selgitab ravimi kasutamist ja kõrvalnähte.
English: Treatment with Increlex should be supervised by doctors who have experience in the diagnosis and treatment of patients with growth disorders.
Estonian: Ravi Increlexiga peab toimuma kasvuhäiretega patsientide diagnoosimises ja ravis kogenud arsti järelevalve all.
English: Why has Increlex been approved?
Estonian: Miks Increlex heaks kiideti?
English: What is Increlex used for?
Estonian: Milleks Increlexi kasutatakse?
English: Increlex is given by injection under the skin, and the injection site should be changed with each injection.
Estonian: Increlexi manustatakse nahaaluse süstina ja iga süste tuleb teha uude kohta.
English: For more information, see the summary of product characteristics.
Estonian: Üksikasjalik teave on ravimi omaduste kokkuvõttes.
English: How has Increlex been studied?
Estonian: Kuidas Increlexi uuriti?
English: Increlex has been authorised under ‘Exceptional Circumstances'.
Estonian: Increlexi müügiluba anti erandkorras.
English: How is Increlex used?
Estonian: Kuidas Increlexi kasutatakse?
English: The full EPAR for Increlex can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Increlexi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Kui vajate Increlexiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Increlex?
Estonian: Mis on Increlex?
English: How does Increlex work?
Estonian: Kuidas Increlex toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Increlex on retseptiravim.
English: Forxiga received a marketing authorisation valid throughout the EU on 11 November 2012.
Estonian: Forxiga on saanud müügiloa, mis kehtib kogu ELis, 11. novembril 2012.
English: Further information on Forxiga can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Forxiga.
Estonian: Lisateave Forxiga kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Forxiga.
English: What measures are being taken to ensure the safe and effective use of Forxiga?
Estonian: Mis meetmed võetakse, et tagada Forxiga ohutu ja efektiivne kasutamine?
English: This overview was last updated in 08-2019.
Estonian: Kokkuvõtte viimane uuendus: 08.2019
English: Other information about Forxiga
Estonian: Muu teave Forxiga kohta
English: Forxiga (dapagliflozin)
Estonian: Forxiga (dapagliflosiin)
English: Why is Forxiga authorised in the EU?
Estonian: Miks Forxiga ELis heaks kiideti?
English: As for all medicines, data on the use of Forxiga are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Forxiga kasutamise kohta pidevat järelevalvet.
English: What is Forxiga and what is it used for?
Estonian: Mis on Forxiga ja milleks seda kasutatakse?
English: Side effects reported with Forxiga are carefully evaluated and any necessary action taken to protect patients.
Estonian: Forxiga kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: For more information about using Forxiga, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Forxiga kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: For type 2 diabetes, the dose of Forxiga is 10 mg once a day.
Estonian: 2. tüüpi diabeedi korral on Forxiga annus 10 mg üks kord ööpäevas.
English: What are the risks associated with Forxiga?
Estonian: Mis riskid Forxigaga kaasnevad?
English: Both combinations reduced HbA1c levels by 0.52 percentage points after 52 weeks.
Estonian: Mõlemad kombinatsioonid vähendasid 52 nädala järel HbA1c väärtust 0,52% võrra.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Forxiga have also been included in the summary of product characteristics and the package leaflet.
Estonian: Forxiga ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Forxiga is a diabetes medicine used for adults whose condition is not controlled well enough.
Estonian: Forxiga on diabeediravim, mida kasutatakse täiskasvanutel, kelle haigus ei ole piisavalt reguleeritud.
English: The company that markets Forxiga will provide information on precautions to prevent diabetic ketoacidosis in patients with type 1 diabetes, including a patient alert card and guide for patients and their carers, as well as a guide for healthcare professionals, including a prescriber's checklist.
Estonian: Forxiga turustaja annab teavet ettevaatusmeetmete kohta diabeetilise ketoatsidoosi ennetamiseks 1. tüüpi diabeediga patsientidel, sealhulgas patsiendi hoiatuskaart, patsientide ja nende hooldajate juhend ning tervishoiutöötajate juhend, sh ravimi määraja kontroll-loetelu.
English: How is Forxiga used?
Estonian: Kuidas Forxigat kasutatakse?
English: For the full list of side effects and restrictions with Forxiga, see the package leaflet.
Estonian: Forxiga kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The main measure of effectiveness was the level of glycosylated haemoglobin (HbA1c), which gives an indication of how well blood glucose is controlled.
Estonian: Efektiivsuse põhinäitaja oli glükohemoglobiin (HbA1c), mis näitab, kui hästi organism reguleerib vere glükoosisisaldust.
English: Adding Forxiga to insulin treatment in patients with type 1 diabetes whose diabetes could not be controlled well enough with insulin was also effective.
Estonian: Forxiga lisamine insuliinravile 1. tüüpi diabeediga patsientidel, kellel insuliin ei reguleerinud diabeeti piisavalt, oli samuti efektiivne.
English: If it is used with insulin or medicines that help the body produce insulin, the doses of these medicines may need to be reduced to decrease the risk of hypoglycaemia (low blood sugar levels).
Estonian: Kasutamisel koos insuliiniga või ravimitega, mis soodustavad insuliini teket organismis, võib olla vaja vähendada nende ravimite annust, et vähendada hüpoglükeemia (vere normaalsest väiksem glükoosisisaldus) riski.
English: In type 2 diabetes, it is used with appropriate diet and exercise in patients who cannot take metformin (another diabetes medicine).
Estonian: 2. tüüpi diabeedi korral kasutatakse seda koos asjakohase dieedi ja füüsilise koormusega patsientidel, kes ei saa võtta metformiini (samuti diabeediravim).
English: The most common side effect in patients with type 1 diabetes (which may affect up to 1 in 10 people) is genital infection, especially in women and a common side effect (which may affect up to 1 in 100 people) is diabetic ketoacidosis.
Estonian: 1. tüüpi diabeediga patsientidel on kõige sagedam kõrvalnäht (võib esineda kuni 1 patsiendil 10st) suguelundite infektsioon, eriti naistel, ja sage kõrvalnäht (võib esineda kuni 1 patsiendil 100st) diabeetiline ketoatsidoos.
English: Precautions have been recommended to reduce the risk of diabetic ketoacidosis and the Agency has asked for further studies to determine its frequency in patients with type 1 diabetes treated with Forxiga.
Estonian: On soovitatud ettevaatusmeetmeid, et vähendada diabeetilise ketoatsidoosi riski, ning amet on nõudnud lisauuringuid, et määrata selle sagedus 1. tüüpi diabeediga patsientidel, keda ravitakse Forxigaga.
English: Diabetes can occur when the body does not make enough insulin to control the amount of glucose (sugar) in the blood or when the body cannot use insulin effectively.
Estonian: Diabeet võib tekkida, kui organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: For type 1 diabetes, treatment with Forxiga should be started and supervised by a specialist in type 1 diabetes.
Estonian: 1. tüüpi diabeedi korral peab ravi Forxigaga alustama ja jälgima 1. tüüpi diabeedi spetsialist.
English: A long-term study, involving over 17,000 patients with type 2 diabetes, looked at the effects of dapagliflozin on cardiovascular (heart and circulation) disease.
Estonian: Pikaajalises uuringus, milles osales üle 17 000 patsiendi, kellel oli 2. tüüpi diabeet, uuriti dapagliflosiini toimet südame-veresoonkonnahaigustele.
English: Forxiga was found effective in several studies in patients with type 2 and type 1 diabetes.
Estonian: Forxiga efektiivsust tõendati mitmes uuringus, milles osalesid 1.ja 2. tüüpi diabeediga patsiendid.
English: The company will also conduct a study to estimate the frequency of diabetic ketoacidosis in patients with type 1 diabetes treated with Forxiga.
Estonian: Ettevõte korraldab ka uuringu, et hinnata diabeetilise ketoatsidoosi sagedust 1. tüüpi diabeediga patsientidel, keda ravitakse Forxigaga.
English: Forxiga increased the risk of diabetic ketoacidosis considerably in patients with type 1 diabetes and it is recommended for this condition only in overweight and obese patients.
Estonian: Forxiga suurendas oluliselt diabeetilise ketoatsidoosi riski 1. tüüpi diabeediga patsientidel ning seda soovitatakse selle seisundi raviks kasutada ainult ülekaalulistel ja rasvunud patsientidel.
English: In type 1 diabetes, Forxiga is used with insulin in overweight patients (body mass index of at least 27 kg/m2) when insulin on its own does not control blood sugar well enough.
Estonian: 1. tüüpi diabeedi korral kasutatakse Forxigat koos insuliiniga ülekaalulistel patsientidel (kehamassiindeks vähemalt 27 kg/m2), kui ainult insuliin ei reguleeri vere glükoosisisaldust piisavalt.
English: In a study involving 814 patients with type 2 diabetes, Forxiga used in combination with metformin was at least as effective as a sulphonylurea (another type of diabetes medicines) used with metformin.
Estonian: Uuringus, milles osales 814 patsienti, kellel oli 2. tüüpi diabeet, oli koos metformiiniga kasutatud Forxiga vähemalt sama efektiivne kui metformiiniga koos kasutatud sulfonüüluurearavim (samuti diabeediravim).
English: Forxiga is available as tablets (5 and 10 mg) and can only be obtained with a prescription.
Estonian: Forxigat turustatakse tablettidena (5 ja 10 mg).
English: The European Medicines Agency considered that Forxiga was effective for treating type 2 diabetes when given alone or in combination with other diabetes medicines which work in different ways.
Estonian: Euroopa Ravimiamet leidis, et Forxiga on 2. tüüpi diabeedi ravimisel efektiivne nii ainuravimina kui ka koos muude diabeediravimitega, mille toimemehhanismid on erinevad.
English: The study indicated that dapagliflozin's effects were in line with those of other diabetes medicines that also work by blocking SGLT2.
Estonian: Uuring näitas, et dapagliflosiini toime sarnaneb samuti SGLT2 toimet blokeerivate muude diabeediravimite toimega.
English: Forxiga contains the active substance dapagliflozin.
Estonian: Forxiga sisaldab toimeainena dapagliflosiini.
English: It can also be used as ‘add-on' treatment to other diabetes medicines.
Estonian: Seda tohib kasutada ka lisaks muudele diabeediravimitele.
English: In two studies involving 1,648 patients with type 1 diabetes whose blood sugar was not controlled well enough on insulin alone, adding Forxiga 5 mg decreased HbA1c levels after 24 hours by 0.37% and by 0.42% more than adding placebo.
Estonian: Kahes uuringus, milles osales 1648 patsienti, kellel oli 1. tüüpi diabeet ja kellel üksnes insuliin ei reguleerinud vere glükoosisisaldust piisavalt, vähendas 5 mg Forxiga lisamine HbA1c väärtust 24 tunni järel 0,37% võrra ja 0,42% võrra rohkem kui platseebo lisamine.
English: What benefits of Forxiga have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Forxiga kasulikkus?
English: Forxiga's common side effects were related to the way the medicine works, such as increased genital and, to a smaller degree, urinary infection, and are considered manageable.
Estonian: Forxiga sagedad kõrvalnähud, näiteks suguelundite ja harvem kuseteede infektsioonid, olid seotud ravimi toimemehhanismiga, kuid neid peetakse hallatavateks.
English: An overview of Forxiga and why it is authorised in the EU
Estonian: Ülevaade ravimist Forxiga ja ELis müügiloa väljastamise põhjendus
English: The Agency concluded that the benefits of Forxiga outweigh its risks and recommended that it be granted marketing authorisation.
Estonian: Euroopa Ravimiamet otsustas, et Forxiga kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: The most common side effect with Forxiga in patients with type 2 diabetes (which may affect more than 1 in 10 people) is hypoglycaemia, especially when used in combination with a sulphonylurea or insulin.
Estonian: 2. tüüpi diabeediga patsientidel on Forxiga kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) hüpoglükeemia, eriti kasutamisel koos sulfonüüluurearavimi või insuliiniga.
English: By blocking the action of SGLT2, dapagliflozin causes the kidney to pass out more glucose in the urine, thereby reducing the levels of glucose in the blood.
Estonian: SGLT2 toimet blokeerides suurendab dapagliflosiin glükoosi eritumist uriiniga, mis vähendab vere glükoosisisaldust.
English: The active substance in Forxiga, dapagliflozin, blocks the action of a protein in the kidneys called sodium-glucose co-transporter 2 (SGLT2).
Estonian: Forxiga toimeaine dapagliflosiin blokeerib neerudes valgu naatriumi-glükoosi kotransporteri 2 (SGLT2) toime.
English: In four other studies involving 2,370 patients, adding Forxiga to other diabetes medicines decreased HbA1c levels by 0.54-0.68 percentage points more than adding placebo after 24 weeks.
Estonian: Neljas muus uuringus, milles osales 2370 patsienti, vähendas muudele diabeediravimitele lisatud Forxiga 24 nädala järel HbA1c väärtust 0,54...0,68% võrra rohkem kui lisatud platseebo.
English: The dose is 5 mg once a day and the medicine should be used with precautions to prevent diabetic ketoacidosis (a serious complication of diabetes with high levels of ketones in the blood).
Estonian: Ravimi kasutamisel peab võtma ettevaatusmeetmeid, et ennetada diabeetilist ketoatsidoosi (raske diabeeditüsistus, mille korral vere ketoonisisaldus on suur).
English: In two studies involving 840 patients with type 2 diabetes, Forxiga when used alone decreased HbA1c levels by 0.66 percentage points more than placebo (a dummy treatment) after 24 weeks.
Estonian: Kahes uuringus, milles osales 840 patsienti, kellel oli 2. tüüpi diabeet, vähendas ainuravimina kasutatud Forxiga 24 nädala järel HbA1c väärtust 0,66% võrra rohkem kui platseebo (näiv ravim).
English: As blood is filtered by the kidneys, SGLT2 stops glucose in the bloodstream from being passed out into the urine.
Estonian: SGLT2 takistab vere filtreerumisel neerudes glükoosi eritumist vereringest uriini.
English: In addition, beneficial reductions in weight and blood pressure occurred in patients treated with Forxiga.
Estonian: Peale selle esines Forxigaga ravitud patsientidel ka muid soodsaid toimeid, näiteks kehakaalu ja vererõhu vähenemist.
English: How does Forxiga work?
Estonian: Kuidas Forxiga toimib?
English: • This medicine is not given to prevent heart disease.
Estonian: • Seda ravimit ei kasutata südamehaiguste ennetamiseks.